Evaluation of microRNA Gene Polymorphisms in Liver Transplant Patients with Hepatocellular Carcinoma

被引:1
|
作者
Dehbidi, Sahar [1 ]
Farokhizadeh, Zhaleh [1 ]
Karimi, Mohammad Hossein [2 ]
Afshari, Afsoon [2 ]
Behmanesh, Mehrdad [3 ]
Sanati, Mohammad Hossein [4 ]
Geramizadeh, Bita [2 ]
Yaghobi, Ramin [2 ]
机构
[1] Nour Danesh Inst Higher Educ, Fac Biol Sci, Dept Biol, Esfahan, Iran
[2] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[3] Tarbiat Modares Univ, Fac Biol Sci, Dept Genet, Tehran, Iran
[4] Natl Inst Genet Engn & Biotechnol, Dept Med Genet, Tehran, Iran
关键词
Hepatocellular Carcinoma; MicroRNA; Liver Transplantation; Rejection; Polymorphism; TURKISH POPULATION; FUNCTIONAL POLYMORPHISM; EXPRESSION PATTERNS; HUMAN CANCER; ASSOCIATION; RISK; INFECTION; SUSCEPTIBILITY; MIR-499A-GREATER-THAN-G; CONTRIBUTES;
D O I
10.5812/hepatmon.102690
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Genetic polymorphism in the miRNA sequence might alter miRNA expression and/or maturation, which is associated with the development and progression of hepatocellular carcinoma (HCC) in liver transplant patients. Objectives: Therefore, the prevalence of miRNA-146a G > C (rs2910164), miRNA-499A > G (rs3746444), miRNA-149C > T (rs2292832), and miRNA-196a-2 C > T (rs11614913) gene polymorphisms was evaluated in liver recipients with HCC with or without experiencing graft rejection. Methods: In a cross-sectional study, tissue samples were collected from 60 HCC patients who underwent liver transplant surgery at Namazi Hospital, Shiraz, Iran, in 2013 - 2015. A control group consisting of 120 individuals was randomly selected, as well. The genomic DNA was extracted from collected tissues and blood samples. The miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) gene polymorphisms were evaluated in patients with HCC using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism were significantly associated with the increased risk of transplant rejection in patients with HCC (P = 0.05 and P = 0.05, respectively). The CC genotype and C allele of the miRNA-146a (rs2910164) were also significantly more frequent in male liver transplant patients who experienced acute rejection than in non-rejected ones (P = 0.05 and P = 0.03, respectively). However, no significant association was found between the genotypes and alleles of miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) polymorphisms and HCC outcomes in liver transplant recipients. Conclusions: The importance of the CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism in increasing the risk of transplant rejection was confirmed, but it needs further studies in larger populations.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [11] Outcomes of Patients With Hepatocellular Carcinoma After Liver Transplant
    Moray, Gokhan
    Kirnap, Mahir
    Akdur, Aydincan
    Soy, Ebru
    Tezcaner, Tugan
    Boyvat, Fatih
    Ozdemir, Handan
    Haberal, Mehmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2015, 13 : 30 - 32
  • [12] Liver Transplant and Hepatocellular Carcinoma
    Gish, Robert G.
    Clinical Advances in Hematology & Oncology, 2016, 14 (12) : 987 - 989
  • [13] Liver transplant versus liver resection in patients with multifocal hepatocellular carcinoma
    Kakish, Hanna
    Suraju, Mohammed O.
    Seth, Abhinav
    DiGioia, Olivia N.
    Pawar, Omkar
    Kwon, Yong K.
    Hemming, Alan W.
    Aziz, Hassan
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (07) : 1062 - 1066
  • [14] PROFILING THE ALTERATIONS IN MICRORNA GENE EXPRESSIONS IN LIVER TRANSPLANT PATIENTS
    Karimi, Mohammad Hossein
    Afshari, Afsoon
    Geramizadeh, Bita
    Malekhosseini, Seyed Ali
    Ebadi, Padideh
    TRANSPLANT INTERNATIONAL, 2015, 28 : 501 - 501
  • [15] Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
    Carrie E. Ryan
    Jacob Lambdin
    Shimul Shah
    Ralph Cutler Quillin
    Kristina Lemon
    Jonathan M. Hernandez
    Davendra Sohal
    Annals of Surgical Oncology, 2023, 30 : 686 - 687
  • [16] Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
    Ryan, Carrie E.
    Lambdin, Jacob
    Shah, Shimul
    Quillin, Ralph Cutler
    Lemon, Kristina
    Hernandez, Jonathan M.
    Sohal, Davendra
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (02) : 686 - 687
  • [17] Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant
    Sohal, Davendra
    Abouelezz, Khaled Fahmy
    Moreland, Katie
    Quillin, Ralph
    Lemon, Kristina
    Rojan, Adam
    Olowokure, Olugbenga Olanrele
    Kord, Ali
    Shah, Shimul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [18] Management of liver transplant patients with recurrence of hepatocellular carcinoma.
    Safak, Adem
    Karakaya, Emre
    Yildirim, Sedat
    Okyay, Ozan
    Boyvat, Fatih
    Tseveldorj, Nomingerel
    Boyacioglu, Sedat
    Haberal, Mehmet A.
    TRANSPLANTATION, 2024, 108 (9S)
  • [19] Surgical resection versus liver transplant for patients with hepatocellular carcinoma
    Taefi, Amir
    Abrishami, Amir
    Nasseri-Moghaddam, Siavosh
    Eghtesad, Bijan
    Sherman, Morris
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
  • [20] BMI AS A PREDICTOR OF HEPATOCELLULAR CARCINOMA RECURRENCE IN LIVER TRANSPLANT PATIENTS
    Higley, Cory
    Abaza, Ehab
    Hsu, Christine C.
    HEPATOLOGY, 2020, 72 : 689A - 690A